ZYNE News and Press, Zynerba Pharmaceuticals Inc.

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE PR Newswire New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders w...

DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to prompt...

DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending ...

2023-09-27 09:20:33 ET More on Harmony Biosciences, Zynerba Pharmaceuticals, etc. Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Bio falls as Goldman Sachs cuts to Sell on revenue risks Harmony Bio expects FDA to reject citizen petition on ...

HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. PR Newswire PLYMOUTH MEETING , Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, I...

2023-09-25 13:08:43 ET More on Harmony Bio Seeking Alpha’s Quant Rating on Harmony Biosciences Financial information for Harmony Biosciences Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences Holdings, Inc. 2023 Q2 - ...

2023-09-24 02:16:31 ET Summary Harmony Biosciences has experienced strong and profitable growth following the approval and commercialization of WAKIX. The company's success has allowed for funding of other programs and acquisitions. Despite the risks associated with dependency...

DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural ...

NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Holly Energy Partners, L.P. (NYS...

NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Earthstone Energy, Inc. (NYSE:ESTE)...